KR101415225B1 - Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same - Google Patents
Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same Download PDFInfo
- Publication number
- KR101415225B1 KR101415225B1 KR1020120064957A KR20120064957A KR101415225B1 KR 101415225 B1 KR101415225 B1 KR 101415225B1 KR 1020120064957 A KR1020120064957 A KR 1020120064957A KR 20120064957 A KR20120064957 A KR 20120064957A KR 101415225 B1 KR101415225 B1 KR 101415225B1
- Authority
- KR
- South Korea
- Prior art keywords
- collagen peptide
- molecular weight
- fish
- average molecular
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 182
- 102000008186 Collagen Human genes 0.000 title claims abstract description 152
- 108010035532 Collagen Proteins 0.000 title claims abstract description 152
- 229920001436 collagen Polymers 0.000 title claims abstract description 151
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title description 18
- 238000000034 method Methods 0.000 claims abstract description 36
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 22
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 244000269722 Thea sinensis Species 0.000 claims abstract description 18
- 235000009569 green tea Nutrition 0.000 claims abstract description 18
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 18
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 18
- 230000008569 process Effects 0.000 claims abstract description 16
- 239000011347 resin Substances 0.000 claims abstract description 16
- 229920005989 resin Polymers 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 238000001179 sorption measurement Methods 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 7
- 239000006227 byproduct Substances 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 6
- 230000006862 enzymatic digestion Effects 0.000 claims abstract description 5
- 235000019688 fish Nutrition 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 239000002994 raw material Substances 0.000 claims description 21
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 14
- 239000003463 adsorbent Substances 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 241000972773 Aulopiformes Species 0.000 claims description 6
- 102000005158 Subtilisins Human genes 0.000 claims description 6
- 108010056079 Subtilisins Proteins 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 230000002255 enzymatic effect Effects 0.000 claims description 6
- 235000019515 salmon Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 241000269821 Scombridae Species 0.000 claims description 2
- 230000007515 enzymatic degradation Effects 0.000 claims description 2
- 235000020640 mackerel Nutrition 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 240000007058 Halophila ovalis Species 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 241001504592 Trachurus trachurus Species 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 26
- 235000013305 food Nutrition 0.000 abstract description 19
- 230000037396 body weight Effects 0.000 abstract description 13
- 235000012000 cholesterol Nutrition 0.000 abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 210000000579 abdominal fat Anatomy 0.000 abstract description 7
- 235000019658 bitter taste Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 description 38
- 210000004185 liver Anatomy 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 235000009200 high fat diet Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 235000019645 odor Nutrition 0.000 description 13
- 208000008589 Obesity Diseases 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 241000276707 Tilapia Species 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 239000003957 anion exchange resin Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- -1 trimethyl amine compound Chemical class 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229960002424 collagenase Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000035943 smell Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 239000003531 protein hydrolysate Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 241000269851 Sarda sarda Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 231100000191 repeated dose toxicity Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ZVNPWFOVUDMGRP-UHFFFAOYSA-N 4-methylaminophenol sulfate Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FDMBBCOBEAVDAO-UHFFFAOYSA-N Stovaine Chemical compound CN(C)CC(C)(CC)OC(=O)C1=CC=CC=C1 FDMBBCOBEAVDAO-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960000806 amylocaine Drugs 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N anhydrous trimethylamine Natural products CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5422—Collagen
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
Abstract
본 발명은 어류 유래 콜라겐 펩티드, 이의 제조방법 및 이의 용도에 관한 것으로, 더욱 상세하게는 어류의 비늘 또는 껍질을 포함하는 원료를 작용부위가 다른 세균 유래 단백분해효소와 곰팡이 유래 단백분해효소를 순차적으로 사용하여 2차에 걸친 효소 분해 공정을 수행하되, 이때 상기 단백질 가수분해 효소와 함께 녹차잎, 이의 추출물 또는 이의 추출 부산물을 첨가하여 효소 분해 공정을 수행하고, 흡착수지 및 이온교환수지의 칼럼을 통과시키는 정제 공정을 거침으로써 분자량이 낮은 콜라겐 펩티드를 얻을 수 있는 어류 유래 콜라겐 펩티드, 이의 제조방법 및 이의 용도에 관한 것이다.
상기 어류 유래 콜라겐 펩티드는 고미(苦味)와 냄새, 색깔이 제거된 고순도의 콜라겐 펩티드로서, 체중 및 복부지방층의 증가를 억제하고, 혈장 총 콜레스테롤 및 트리글리세리드의 함량을 감소시키는 효과가 우수하여, 비만 예방 및 치료 또는 개선에 유용한 의약품 및 식품으로 사용될 수 있다.The present invention relates to a fish-derived collagen peptide, a method for producing the same, and a use thereof, and more particularly, to a fish-derived collagen peptide, The enzymatic digestion process is performed by adding green tea leaves, its extract or its by-products, together with the protein hydrolyzing enzyme, and passing through the columns of the adsorption resin and the ion exchange resin To a collagen peptide having a low molecular weight by subjecting the collagen peptide to a purification process, and a method for producing the collagen peptide, and a use thereof.
The fish-derived collagen peptide is a high-purity collagen peptide from which bitterness, odor, and color have been removed. The fish-derived collagen peptide has excellent effects of suppressing the increase in body weight and abdominal fat layer and reducing plasma total cholesterol and triglyceride content, And as medicaments and foods useful for treatment or improvement.
Description
본 발명은 어류의 비늘 또는 껍질로부터 유래되며 색깔, 냄새가 없고 비만 예방 및 치료에 효과적인 어류 유래 콜라겐 펩티드, 이의 제조방법 및 이의 용도에 관한 것이다.The present invention relates to fish-derived collagen peptides derived from scales or peels of fish, which are free from color, odor and which are effective for the prevention and treatment of obesity, a process for their preparation and their use.
콜라겐은 단백질의 일종으로, 가늘고 긴 섬유 모양을 하고 있으며, 분자량이 약 10만 가량인 폴리펩티드 사슬이 3개 모여서 이루어진 나선구조의 고분자 단백질이다. 상기 콜라겐은 피부의 진피층과 결합조직의 주성분이며 피부의 70%를 차지하고 있고, 뼈를 구성하고 있는 단백질 중 90% 및 뼈 중량의 20%를 차지하고 있다. 이러한 콜라겐은 고분자인 그 자체로서도 사용되나 최근에는 저분자화된 콜라겐 펩티드가 다양한 식품, 화장품 용도로 사용되고 있다.Collagen is a kind of protein. It is a spiral-structured macromolecule protein with three long chains of polypeptides with a molecular weight of about 100,000. The collagen is the main component of the dermal layer and the connective tissue of the skin, which accounts for 70% of the skin, 90% of the proteins constituting the bone, and 20% of the bone weight. Such collagen is also used as a polymer itself, but recently, a low molecular weight collagen peptide has been used for various food and cosmetic applications.
콜라겐 펩티드 제조에 있어서 종래의 기술은 단백질 가수분해물이나 젤라틴 또는 콜라겐을 제조할 때, 소 혹은 유사 반추 동물의 뼈나 껍질을 사용하여 기능성 식품첨가물 및 화장품용 원료를 제조하여 왔다. Conventional techniques in the production of collagen peptides have produced functional food additives and raw materials for cosmetics by using bones or bark of cattle or similar ruminants when preparing protein hydrolysates, gelatin or collagen.
그러나 광우병(BSE, Bovine Spongiform Encephalopathy)의 발병을 계기로 한국식품안전청, 유럽 식품안정청, 미국 식품안정청 및 일본 후생성 등에서는 광우병 발병 위험이 큰 나라로부터 해당 원료를 수입하거나 반입 또는 사용을 금지하게 되었다. However, due to the onset of BSE (BSE, Bovine Spongiform Encephalopathy), Korea Food Safety Agency, European Food Safety Agency, US Food Safety Agency and Japan Ministry of Health and Welfare have been prohibited from importing, importing or using the raw materials from countries with high risk of mad cow disease.
또한, 돼지나 닭과 같은 가축을 이용한 단백질 가수분해물도 돼지 콜레라(Swine fever) 또는 조류 인플루엔자(Pathogenic avian influenza) 등의 발병으로 인하여 점차 그 사용을 금지하는 추세이다. 따라서, 광우병, 돼지 콜레라 또는 조류 인플루엔자 등의 위험이 없는 안전한 천연의 해양성 생물이나 식물 유래의 콜라겐 또는 단백질 가수분해물 등에 대한 관련기술의 개발 또는 연구가 활발하게 이루어져 왔다. In addition, protein hydrolysates using livestock such as pigs and chickens are gradually prohibited from use due to the occurrence of swine fever or pathogenic avian influenza. Accordingly, there has been actively developed or studied research on safe natural marine organisms or plant-derived collagen or protein hydrolysates free from danger such as mad cow disease, swine cholera or avian influenza.
특히 어류의 비늘이나 껍질이나 비늘에서의 콜라겐 펩티드는 활발히 상업화가 진행되어 왔다. 그러나 어류 비늘이나 껍질로부터 유래한 콜라겐이나 그 가수분해물들은 우피와 돈피로부터 유래한 콜라겐에 비하여 특유의 냄새, 색깔 등 때문에 식품, 화장품 또는 의약품 소재 분야에서 사용하기 어려운 것으로 알려져 있다. 또한, 지방성 물질 또는 단백질 변성 온도 등으로 인하여 투명도가 떨어지는 등 품질이 저하되는 경우도 있어, 탈취, 탈색된 고순도의 콜라겐 펩티드를 제조하는 것이 중요하다. In particular, collagen peptides in fish scales, bark and scales have been actively commercialized. However, collagen and its hydrolysates derived from fish scales and shells are known to be difficult to use in foods, cosmetics or pharmaceuticals because of their distinctive odor and color as compared with collagen derived from wheat and pork. In addition, the quality may be deteriorated due to a decrease in transparency due to an aliphatic substance or a protein denaturation temperature, etc., and it is important to produce deodorized and decolorized high-purity collagen peptides.
종래의 콜라겐 펩티드는 유사한 제조 공정을 사용하여 제조되고 있다.Conventional collagen peptides are produced using similar manufacturing processes.
대한민국 특허등록 제10-0532153호는 어류 비늘을 이용한 단백질 가수분해물을 제조하는 방법으로, 여기에서는 탈재, 탈단백 공정인 산, 알칼리 처리단계와 가수분해효소로는 엔도형 가수분해효소로 펩신, 트립신, 파파인, 콜라게나제 또는 카텝신을 사용하였으며, 이때 얻어지는 콜라겐 펩티드는 분자량이 500∼10,000인 것을 특징으로 하고 있다.Korean Patent Registration No. 10-0532153 discloses a method for producing protein hydrolyzate using fish scales. In this process, the acid and alkali treatment steps of the deprotection and deproteinization processes and hydrolysis enzymes such as pepsin, trypsin , Papain, collagenase or cathepsin were used, and the obtained collagen peptide had a molecular weight of 500 to 10,000.
대한민국 특허등록 제10-0647033호에 의하면 우피(Hide Splits), 돈피(Pig Skin), 건조된 소뼈(Ossein), 어류 등을 원료로 사용하였으며, 산, 알칼리 전처리와 열수 추출 후 바실러스 서브틸리스 계통의 효소를 사용하고, 펌프로 1, 2차 여과, 카본필터로 3, 4차 여과하여 이취를 제거한 다음, 살균과 스프레이 드라이어로 건조하는 단계로 콜라겐 펩티드를 제조하는 방법을 기술하고 있다.According to Korean Patent Registration No. 10-0647033, as a raw material, Hide Splits, Pig Skin, dried bones (Ossein) and fish were used as raw materials. After acid and alkaline pretreatment and hot water extraction, Bacillus subtilis line Of the enzyme is used, and the resulting product is subjected to first and second filtration with a pump, third and fourth filtration with a carbon filter to remove odors, and then sterilization and drying with a spray dryer to produce a collagen peptide.
또한, 대한민국 특허등록 제10-0699324호에 의하면 생선 비늘을 사용하고, 산, 알칼리를 이용한 전처리를 수행하고, 이어서 바실러스 리케니포르미스 유래 알칼라제 효소(0.05∼0.6중량%, pH 7, 40∼70℃, 1∼48 시간 처리)를 사용하여 분자량 500∼10,000인 콜라겐 펩티드를 제조하는 방법이 기술되어 있다. According to Korean Patent Registration No. 10-0699324, fish scales were used and pretreatment was carried out using acid and alkali. Then, an enzyme (0.05 to 0.6 wt%,
그리고 대한민국 특허등록 제10-0492371호는 돈피를 원료로 바실러스 리케니포르미스 및 바실러스 아밀로쿠에파시엠스 유래 유사한 효소로 2단계 효소 반응하여 분자량 1,000 내지 2,000인 콜라겐 펩티드를 제조하는 기술이 기재되어 있으며, 대한민국 특허등록 제10-0488913호에서는 식물성 및 마린 유래 원료를 사용하고 효소는 트립신 및 파파인을 사용하여 분자량 1,000∼5,000의 콜라겐 펩티드를 제조하는 기술을 개시하고 있다.Korean Patent Registration No. 10-0492371 discloses a technique for producing a collagen peptide having a molecular weight of 1,000 to 2,000 by reacting a raw material of pork with a two-step enzyme with a similar enzyme derived from Bacillus licheniformis and Bacillus amylocaine pacemus , Korean Patent Registration No. 10-0488913 discloses a technique for producing a collagen peptide having a molecular weight of 1,000 to 5,000 by using raw materials derived from vegetable and marine and using enzymes such as trypsin and papain.
대한민국 특허등록 제10-1020312호에는 산/염기 가수분해에 의한 전처리 공정 없이 탈재된 어류 비늘에 바실러스 리케니포르미스 유래 알칼라제 및 바실러스 유래 프로타멕스를 함께 또는 순차처리하여 효소 가수분해하는 단계를 포함하는 어류 비늘 콜라겐 펩티드의 제조방법을 개시하고 있는 등, 다양한 콜라겐 펩티드 제조법이 있으나 탈취 탈색에 대한 근본적인 공정적용은 구체적으로 명시된 경우가 드물다.Korean Patent Registration No. 10-1020312 discloses a process for enzymatic hydrolysis of fish scales removed without pretreatment by acid / base hydrolysis together with or simultaneously treating Bacillus licheniformis-derived alcalase and Bacillus-derived protamase And a method of producing collagen peptide of fish scale including a fish scale collagen peptide, which comprises a method of producing collagen peptide of the present invention. However, the application of a fundamental process for deodorization and decolorization is rarely specified.
또한, 일본 특허공개 제2007-246460호에서 펩티드 Gly-X-Y를 함유하는 펩티드 혼합물을 알칼리성 음이온교환수지와 접촉하여 새 펩티드 Gly-X-Y를 흡착시킨 후, 이를 용출함으로써 새 펩티드 Gly-X-Y의 함유율이 상기 펩티드 혼합물보다 높일 수 있다고 개시하고 있다.Further, in Japanese Patent Application Laid-Open No. 2007-246460, a peptide mixture containing a peptide Gly-XY is contacted with an alkaline anion exchange resin to adsorb a new peptide Gly-XY and then eluted, whereby the content of the new peptide Gly- Lt; / RTI > peptide mixture.
그리고 일본 특허공개 제2008-024611호에 펩티드 혼합물에 함유되는 일부 소수성 펩티드를 비극성 흡착제에 흡착시켜, 상기 비극성 흡착제에 흡착하지 않았던 친수성 새 펩티드 Gly-X-Y를 회수함으로써 친수성 새 펩티드 Gly-X-Y의 함유율이 상기 펩티드 혼합물보다 높일 수 있는 펩티드 정제물의 제조방법을 언급하고 있다.Japanese Patent Application Laid-Open No. 2008-024611 discloses that a hydrophobic peptide Gly-XY is adsorbed on a nonpolar adsorbent by adsorbing some hydrophobic peptides contained in a peptide mixture to recover a hydrophilic new peptide Gly-XY that has not adsorbed on the nonpolar adsorbent Refers to a process for preparing peptide peptides which can be higher than the peptide mixture.
한편, 콜라겐 단백질은 히드록시프롤린이나 히드록시리신 등 콜라겐 특유의 아미노산을 갖는 반면, 필수 아미노산인 트립토판을 갖지 않기 때문에, 아미노산 스코어가 제로이고, 영양소로서는 역사적으로 주목받지 못하였다. On the other hand, the collagen protein has a collagen-specific amino acid such as hydroxyproline or hydroxylysine, while it does not have an essential amino acid tryptophane. Therefore, the amino acid score is zero, and it is not historically attracted attention as a nutrient.
그러나 다니구찌 등은 콜라게나제 처리에 의한 콜라겐의 분해물(펩티드 혼합물)과 동일 비율의 아미노산 혼합물에 대하여 각각 랫트에 있어서의 피부 콜라겐의 합성 촉진 효과를 비교 검토한 결과, 아미노산 혼합물에서는 효과가 보이지 않고 콜라게나제에 의한 분해물에서만 효과가 보인 것을 보고하였다. 이러한 결과는 콜라게나제에 의한 분해물의 생리 작용이나 약리 작용은 아미노산으로서 체내에 흡수되어 단백질이 재구성됨으로써 발휘되는 것은 아니고, 펩티드 자체에 의해서 발휘됨을 시사한다.However, Daniguchi et al. Both examined the effect of accelerating the synthesis of skin collagen in rats on the same amount of amino acid mixture as collagen degradation product (peptide mixture) by collagenase treatment. As a result, Collagenase and the degradation products by collagenase. These results suggest that the physiological or pharmacological action of the degradation product by the collagenase is absorbed into the body as an amino acid and is not exerted by reconstitution of the protein, but is exerted by the peptide itself.
지금까지 콜라겐 또는 콜라겐 펩티드의 생리 작용이나 약리 작용으로서, 골다공증의 예방ㆍ개선에 결부되는 골아 세포 증식 촉진 작용, 뼈 강화 작용, 노화에 따른 생체 조직 기능의 저하를 개선하는 생체 조직의 신진 대사 촉진 작용, 피부 대사 촉진 작용 등이 밝혀지고 있다. 최근 콜라겐 펩티드의 이와 같은 수많은 생리 작용이나 약리 작용이 발견되어, 화장품 및 식품용 원재료나 기능성 재료로서 폭넓게 이용되고 있다. As the physiological action and pharmacological action of collagen or collagen peptide so far, osteoclast proliferation promoting action associated with prevention and amelioration of osteoporosis, bone strengthening action, and metabolism promoting function of biotissue which improves deterioration of biotissue function due to aging , And skin metabolism promoting action. Recently, many physiological and pharmacological actions of collagen peptides have been discovered, and they have been widely used as raw materials for cosmetics and foods, and functional materials.
한편, 비만은 전세계에 걸쳐서 빠르게 확산되어 사회 경제적으로 부담이 증가하고 있는 질병으로 당뇨병, 심장질환, 뇌졸증 또는 암과 같은 심각한 질병을 야기한다. Obesity, on the other hand, is a rapidly spreading socioeconomic burden throughout the world, causing serious illnesses such as diabetes, heart disease, stroke or cancer.
콜라겐 또는 콜라겐 펩티드 성분은 상기 기술한 바와 같이 다양한 성인병 예방기능이 있으나, 콜라겐 펩티드 성분이 가지는 항비만 효과는 거의 보고되지 않았다. As described above, collagen or collagen peptide components have various preventive functions against adult diseases, but the anti-obesity effect of collagen peptide components is hardly reported.
이에 본 발명자들은 고순도 콜라겐 펩티드를 제조하면서 이들의 기능을 탐구하던 중 어류로부터 효소 처리에 의해 고미(苦味)와 냄새, 색깔이 제거된 콜라겐 펩티드를 분리하고, 이 물질이 지방 대사에 관여하여 비만을 억제, 개선하여 약학적 및 식품 용도에 사용 가능함을 알아내어 본 발명을 완성하였다.Accordingly, the inventors of the present invention have been studying their functions while producing high purity collagen peptides, and have succeeded in separating the collagen peptides from the fish by enzymatic treatment to remove the bitterness, odor and color, and this substance is involved in fat metabolism, Inhibition, and improvement of the pharmaceutical composition of the present invention, and thus the present invention has been completed.
따라서, 본 발명은 어류로부터 고순도의 콜라겐 펩티드를 제조하는 방법을 제공하는 것을 목적으로 한다.Accordingly, it is an object of the present invention to provide a method for producing high purity collagen peptide from fish.
또한, 본 발명은 상기 방법으로부터 얻어지는 어류 유래 콜라겐 펩티드 및 이의 용도를 제공하는 것을 다른 목적으로 한다.It is another object of the present invention to provide a fish-derived collagen peptide obtained from the above method and its use.
상기 목적을 달성하기 위해, 본 발명은 In order to achieve the above object,
어류의 비늘 또는 껍질을 포함하는 원료를 단백질 가수분해 효소와 함께 녹차잎, 이의 추출물 또는 이의 추출 부산물을 첨가하여 효소 분해 공정을 수행 후 여과하여 콜라겐 펩티드 여과물을 얻는 단계;Adding a green tea leaf, an extract thereof or an extractive by-product of the green tea leaf together with a protein hydrolyzing enzyme to a raw material containing fish scales or a shell, performing an enzymatic decomposition process, and then filtering to obtain a collagen peptide filtrate;
상기 콜라겐 펩티드 여과물을 흡착수지 및 이온교환수지에 통과시켜 정제하는 단계; 및 Passing the collagen peptide filtrate through an adsorption resin and an ion exchange resin to purify the collagen peptide filtrate; And
농축, 건조하여 콜라겐 펩티드를 회수하는 단계를 포함하는 어류 유래 콜라겐 펩티드의 제조방법을 제공한다.Concentrating, and drying the collagen peptide to recover the collagen peptide. The present invention also provides a method for producing a fish-derived collagen peptide.
또한, 본 발명은 상기 방법으로 얻어지며, 평균분자량이 90∼2800이며, 이때 평균분자량 1500 이하의 펩티드가 전체 조성 내에서 65 중량％ 이상으로 이루어지는 어류 유래 콜라겐 펩티드를 제공한다.The present invention also provides a fish-derived collagen peptide, which is obtained by the above-mentioned method and has an average molecular weight of 90 to 2800, wherein the peptide having an average molecular weight of 1,500 or less is contained in an overall composition of 65% by weight or more.
또한, 본 발명은 상기 어류 유래 콜라겐 펩티드를 유효 성분으로 포함하는 비만 치료 및 예방용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the treatment and prevention of obesity comprising the fish-derived collagen peptide as an active ingredient.
또한, 본 발명은 상기 어류 유래 콜라겐 펩티드를 유효 성분으로 포함하는 비만 예방 및 개선용 식품 조성물을 제공한다.The present invention also provides a food composition for prevention and improvement of obesity comprising the fish-derived collagen peptide as an active ingredient.
본 발명에 따른 어류 유래 콜라겐 펩티드는 고미(苦味)와 냄새, 색깔이 제거된 고순도의 콜라겐 펩티드로서, 종래 콜라겐 펩티드에 비해 저분자로 구성된 올리고펩티드로 구성된다. The fish-derived collagen peptide according to the present invention is a high-purity collagen peptide having a bitterness, smell and color removed, and is composed of oligopeptides composed of low molecular weight as compared with conventional collagen peptides.
이러한 어류 유래 콜라겐 펩티드는 체중 및 복부지방층의 증가를 억제하고, 혈장 총 콜레스테롤 및 트리글리세리드의 함량을 감소시키는 효과가 우수하여, 비만 예방 및 치료 또는 개선에 유용한 의약품 및 식품으로 사용될 수 있다.Such fish-derived collagen peptides can be used as medicines and foods which are effective in preventing or treating obesity, and having excellent effects of suppressing the increase in body weight and abdominal fat layer and reducing the content of plasma total cholesterol and triglyceride.
도 1은 (a) 실시예 1, (b) 비교예 1 및 (c) 비교예 2의 콜라겐 펩티드의 분자량 분포를 보여주는 그래프이다.
도 2는 (a) 실시예 1, (b) 비교예 1 및 (c) 비교예 2의 콜라겐 펩티드의 평균 분자량 분포를 보여주는 그래프이다.FIG. 1 is a graph showing the molecular weight distribution of the collagen peptide of (a) Example 1, (b) Comparative Example 1 and (c) Comparative Example 2. FIG.
2 is a graph showing the average molecular weight distribution of collagen peptides of (a) Example 1, (b) Comparative Example 1 and (c) Comparative Example 2.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에서는 어류로부터 고미(苦味)와 냄새, 색깔을 제거하고 고순도의 저분자 콜라겐 펩티드를 얻고, 이를 비만 예방, 개선 및 치료 용도로 사용함을 제시한다. In the present invention, it is proposed to remove the bitterness, odor and color from fish and to obtain a high-purity low molecular weight collagen peptide and to use it for prevention, improvement and treatment of obesity.
상기 콜라겐 펩티드는 어류의 비늘 또는 껍질을 포함하는 원료를 단백질 가수분해 효소와 함께 녹차잎, 이의 추출물 또는 이의 추출 부산물을 첨가하여 효소 분해 공정을 수행 후 여과하여 콜라겐 펩티드 여과물을 얻는 단계; 상기 콜라겐 펩티드 여과물을 흡착수지 및 이온교환수지에 통과시켜 정제하는 단계; 및 농축, 건조하여 콜라겐 펩티드를 회수하는 단계를 거쳐 제조되며, 이하 각 단계별로 상세히 설명한다.
Wherein the collagen peptide is obtained by adding a green tea leaf, an extract thereof or an extractive by-product of the green tea leaf together with a protein hydrolyzing enzyme to a raw material containing fish scales or shells, and performing an enzymatic decomposition process to obtain a collagen peptide filtrate; Passing the collagen peptide filtrate through an adsorption resin and an ion exchange resin to purify the collagen peptide filtrate; And concentrating and drying to recover the collagen peptide, which will be described in detail below.
먼저, 콜라겐 펩티드를 얻기 위해, 원료의 전처리 과정을 수행한다.First, in order to obtain a collagen peptide, a pretreatment process of a raw material is performed.
원료로 사용가능한 어류는 본 발명에서 특별히 한정하지 않으며, 연어, 송어 등의 연어목 연어과, 참치, 가다랭이 등의 농어목 고등어과, 방어 등의 농어목 전갱이과, 틸라피아 등의 농어목 시크리드과, 대구, 명태 등의 대구목 대구과 등이 가능하며, 본 발명의 실시예에서는 틸라피아(Tilapia)를 사용하였다.The fish which can be used as raw materials are not particularly limited in the present invention, and fish such as salmon, trout, salmon, salmon, tuna, bonito and other sea mackerels such as salmon, bonito and tilapia, And the like. In the embodiment of the present invention, Tilapia is used.
원료로서 어류의 비늘 또는 껍질을 물로 여러 번 세척을 수행하여 냄새를 완전히 제거한다.
As a raw material, scales or bark of fish are washed several times with water to completely remove the smell.
다음으로, 전처리가 끝낸 원료를 효소 분해 공정을 수행하여 콜라겐 펩티드 여과물을 얻는다.Next, the pretreated raw material is subjected to an enzymatic decomposition step to obtain a collagen peptide filtrate.
효소 분해를 통해 콜라겐을 포함한 단백질이 가수분해되면 펩티드가 생성되며 이때 펩티드의 조성, 종류에 따라 여러 가지 생체 기능을 가지게 될 수 있다. When a protein including collagen is hydrolyzed through enzymatic degradation, a peptide is produced. Depending on the composition and type of the peptide, the protein may have various biological functions.
상기 효소 분해 공정은 단백질 가수분해 효소가 사용될 수 있으며, 이때 상기 효소는 그 기원이나 종류에 따라 작용하는 기질 단백질 아미노산의 위치가 다르므로 저분자화를 위해서는 단일 효소보다는 가수분해 작용 위치가 다른 다양한 효소를 2 내지 4종 사용하는 것이 유리하다. Since the enzymatic decomposition process may use a protein hydrolyzing enzyme, the position of the substrate protein amino acid acting depending on the origin and type of the enzyme is different. Therefore, in order to achieve low molecular weight, various enzymes having different hydrolysis sites It is advantageous to use 2 to 4 species.
바람직하기로, 상기 단백질 가수분해 효소로는 세균 유래 단백분해효소와 곰팡이 유래 단백분해효소를 순차적으로 2차에 걸친 효소 분해 공정으로 수행한다.Preferably, the proteolytic enzyme is a proteolytic enzyme derived from bacteria and a proteolytic enzyme derived from fungus, which are sequentially subjected to a second enzymatic digestion process.
본 발명에서는 바실러스(Bacillus) 유래의 단백분해효소인 알칼라제(Alcalase)를 원료 1kg에 대해 0.001∼25g, 바람직하게는 10g을 사용하여 20℃∼80℃, 바람직하게는 60℃에서 3∼24시간, 바람직하게는 6시간 처리하였다. 이어서, 아스퍼질러스(Aspergillus) 유래의 단백분해 효소인 수미자임(Sumizyme) AP를 원료 1kg에 대해 0.001∼25g, 바람직하게는 10g을 사용하여 20℃∼60℃, 바람직하게는 40℃에서 3∼24시간, 바람직하게는 6시간 처리하였다.In the present invention, the amount of Alcalase , a protease derived from Bacillus, is 0.001 to 25 g, preferably 10 g, per 20 kg of the raw material, preferably 20 to 80 캜, preferably 60 to 3 캜, For a period of time, preferably 6 hours. Then, Sumizyme AP, a protease derived from Aspergillus , is added at a temperature of 20 to 60 ° C, preferably 40 ° C to 3 to 20 ° C, using 0.001 to 25 g, preferably 10 g per 1 kg of the raw material. 24 hours, preferably 6 hours.
만약 상기 단백분해효소의 함량이 상기 범위 미만이면 충분한 가수분해 처리가 이루어지지 않아 펩티드를 높은 함량으로 얻을 수 없고, 상기 범위를 초과하더라도 그 효과가 중량 대비하여 크게 증가하지 않으므로, 상기 범위 내에서 적절히 사용한다.If the content of the protease is less than the above range, sufficient hydrolysis can not be carried out and the peptide can not be obtained in a high content. If the content exceeds the above range, the effect does not significantly increase with respect to weight. use.
이러한 효소처리 공정을 통해 저분자화된 콜라겐 펩티드를 회수할 수 있다. This enzyme treatment process can recover the low molecular weight collagen peptide.
그러나 어류의 비늘이나 껍질은 선도가 저하하면 비린 냄새 같은 이상취가 되고 다음에 암모니아 냄새를 발생한다. 어류의 악취를 대표하는 성분은 트리메틸아민(trimethyl amine)류 화합물로 이 물질의 냄새 지각가능 경계농도는 0.00021 ppm으로 대단히 낮으며 이외에도 다양한 어취 성분이 생성된다. However, the scale or skin of a fish has a bad smell when it is lowered, and then smells of ammonia. The representative odor of fish is trimethyl amine compound. The odor of this substance is very low at 0.00021 ppm boundary concentration, and various catch components are produced.
또한, 효소반응 중에는 고온에 의한 지방의 산패, 갈변 작용과 함께 고미를 가진 방향족 아미노산 등의 생성이 유발될 수 있으며 이러한 불순물들은 반응 후 정제공정만으로 제거하기가 쉽지 않다. In addition, during the enzymatic reaction, it may lead to the formation of fatty acids, browning, and aromatic amino acids with high temperature, and these impurities are difficult to remove only by the purification process after the reaction.
따라서, 본 발명에서는 효소분해에 의해 제조된 용해성 콜라겐 펩티드의 순도를 높이고, 초기 세척에 의해 제거되지 않은 냄새, 색 등과 반응중 생성되는 불순물 제거를 위해 탈취제로서 녹차잎, 이의 추출물 또는 이의 추출 부산물을 효소와 함께 투입하였다. 이러한 녹차잎 등은 총 폴리페놀의 양이 녹차재료 g당 50mg 이상의 것이면 사용할 수 있다. Therefore, in the present invention, in order to increase the purity of the soluble collagen peptide produced by enzyme digestion and to remove the impurities such as odor, color and the like which have not been removed by the initial washing and the impurities generated during the reaction, the green tea leaves, their extracts or their by- And added with the enzyme. Such green tea leaves can be used if the total amount of polyphenol is 50 mg or more per gram of green tea material.
이때 녹차 추출물은 녹차로부터 다양한 추출 공정을 통해 유용 성분을 추출한 조성을 의미하고, 추출 부산물은 추출 후 남은 잔사를 의미한다. 상기 추출 공정은 당업계에 알려진 다양한 열수추출, 실온추출, 가온추출, 초음파추출, 또는 초임계추출 등의 방법이 사용될 수 있다.In this case, the green tea extract means a composition obtained by extracting useful components from green tea through various extraction processes, and the by-product of extraction means the residue left after extraction. The extraction process may be performed by a variety of methods known in the art such as hot water extraction, room temperature extraction, warming extraction, ultrasonic extraction, or supercritical extraction.
상기 녹차잎 등은 원료(어류 비늘, 껍질 등) 원료 1kg에 대해 0.01∼500g, 바람직하게는 100g을 사용한다. 만약 상기 탈취제의 함량이 상기 범위 미만이면 충분한 탈취 효과를 얻을 수 없고, 상기 범위를 초과하더라도 그 효과가 중량 대비하여 크게 증가하지 않으므로, 상기 범위 내에서 적절히 사용한다.The green tea leaves are used in an amount of 0.01 to 500 g, preferably 100 g per 1 kg of raw material (fish scale, shell, etc.). If the content of the deodorant is less than the above range, a sufficient deodorizing effect can not be obtained. If the deodorant content exceeds the above range, the effect does not greatly increase with respect to weight.
이때 원료는 물에 현탁하며, 건조 중량 대비 5∼50%의 농도, 바람직하기로 30%의 농도로 사용한다.
The raw material is suspended in water and used at a concentration of 5 to 50%, preferably 30%, based on the dry weight.
다음으로, 이전 단계에서 얻어진 콜라겐 펩티드 여과물을 흡착수지 및 이온교환수지에 통과시켜 정제 공정을 수행한다.Next, the collagen peptide filtrate obtained in the previous step is passed through an adsorption resin and an ion exchange resin to carry out a purification process.
상기 효소분해 처리로 얻어진 콜라겐 펩티드 여과물은 용해성 콜라겐 펩티드 이외에 녹차성분과 결합한 냄새, 색깔 등의 불순물 등 다양한 불순물을 함유하고 있다. 콜라겐 펩티드 순도를 높이고, 폴리페놀 등 녹차성분과 결합한 냄새, 색 등 불순물의 제거가 필요하다.The collagen peptide filtrate obtained by the above enzyme decomposition treatment contains various impurities such as impurities such as odor and color combined with the green tea component in addition to the soluble collagen peptide. It is necessary to increase the purity of the collagen peptide and to remove the impurities such as odor and color combined with the green tea component such as polyphenol.
이러한 불순물은 이온교환수지, 바람직하기로 약산성 양이온교환수지, 약염기성 음이온교환수지, 및 흡착수지를 순차적으로 통과시켜 제거하고, 이때 상기 이온교환수지와 흡착수지의 순서 배치는 서로 바꾸어도 무방하다.Such impurities may be removed by sequentially passing through an ion exchange resin, preferably a weakly acidic cation exchange resin, a weakly basic anion exchange resin, and an adsorption resin, wherein the order of arrangement of the ion exchange resin and the adsorption resin may be reversed.
사용가능한 약산성 양이온교환수지, 약염기성 음이온교환수지, 및 흡착수지는 본 발명에서 특별히 한정하지 않으며, 공지되거나 시판되는 교환수지 또는 흡착수지면 어느 것이든 사용가능하다.The usable weakly acidic cation-exchange resin, weakly basic anion-exchange resin, and adsorbent resin are not particularly limited in the present invention, and any known or commercially available exchange resin or adsorbent can be used.
특히, 본 발명에서 흡착수지 및 이온교환수지를 이용한 콜라겐 펩티드 여과물의 처리는 종래와는 다른 방식으로 진행한다. 즉, 일반적인 콜라겐 펩티드는 이온교환수지에 흡착시킨 후 용출시켜 정제하는 공정으로 이루어지나, 본 발명에서는 빠른 속도로 소량의 약산성 양이온 및 약염기성 음이온교환수지에 통과시킴으로써 폴리페놀 등 녹차성분과 결합한 냄새, 색 등을 불순물을 흡착시킨다.Particularly, in the present invention, the treatment of the collagen peptide filtrate using the adsorption resin and the ion exchange resin proceeds in a different manner from the conventional method. That is, a general collagen peptide is adsorbed on an ion exchange resin, followed by elution and purification. In the present invention, by passing a small amount of a weakly acidic cation and a weakly basic anion exchange resin at a high speed, Color and so on.
본 발명의 실험예에서는 합성 흡착제로 HP20를 사용하였고, 약산성 이온교환수지로 Diaion WK60L을 사용하였고, 약염기성 이온교환수지로 Trilite AW90을 사용하였으나, 이들에 의해 종류가 한정되지는 않는다. 상기 흡착수지는 HP20를 원료 중량 대비 1∼6배 바람직하게는 3배의 양으로 충진한 컬럼에 SV1∼SV2의 속도로 통과시키고, 약산성 및 약염기성 이온교환수지에 이온교환수지는 원료 중량 대비 각각 0.5∼2배 바람직하게는 1배의 양을 충진한 각각의 컬럼에 SV3∼SV5의 속도로 통과시킨다.In the experimental example of the present invention, HP20 was used as a synthetic adsorbent, Diaion WK60L was used as a weakly acidic ion exchange resin, and Trilite AW90 was used as a weakly basic ion exchange resin. The adsorbent resin is passed through a column packed with HP20 in an amount of 1 to 6 times, preferably 3 times the weight of the raw material, at a rate of SV1 to SV2, and the ion exchange resin is added to the weakly acidic and weakly basic ion- Is passed through each column filled with 0.5 to 2 times, preferably 1 time, at a rate of SV3 to SV5.
이러한 이온교환수지 및 흡착수지를 거쳐 정제된 콜라겐 펩티드는 추가로 활성탄, 활성 백토, 알루미나 등을 처리하지 않아도 냄새, 색, 맛의 제거 정도가 우수하다.
The collagen peptide purified through the ion exchange resin and the adsorbent resin is excellent in the degree of elimination of odor, color, and taste without further treatment of activated carbon, activated clay, alumina and the like.
다음으로, 상기 이온교환수지 및 흡착수지를 거쳐 정제된 콜라겐 펩티드를 농축, 건조하여 회수한다.Next, the collagen peptide purified through the ion exchange resin and the adsorption resin is concentrated, dried and recovered.
상기 농축 및 건조는 본 발명에서 특별히 한정하지 않으며 통상의 방법에 의한, 즉 한외여과막, 감압농축 등의 방법과 동결건조, 분무건조 등의 방법으로 회수하고, 필요한 경우 분말화 공정을 통해 분말 상태로 회수할 수 있다.
The concentration and drying are not particularly limited in the present invention, and may be recovered by a conventional method, that is, a method such as an ultrafiltration membrane or a reduced pressure concentration method, a freeze drying method, a spray drying method and the like, Can be recovered.
상기한 방법을 거쳐 얻어진 콜라겐 펩티드는 분자량 2800 이하의 펩티드가 100 중량％, 분자량 1500 미만의 펩티드가 전체 조성 내에서 65 중량％ 이상으로 이루어진다.The collagen peptide obtained by the above-mentioned method has 100% by weight of a peptide having a molecular weight of 2800 or less and a peptide having a molecular weight of less than 1500 in an overall composition of 65% by weight or more.
이러한 콜라겐 펩티드는 냄새, 색깔, 고미가 제거되고, 저분자 비율이 높아 수용성이 크게 증가하여, 의약, 식품 등 여러 분야에 적용이 가능하다. Such collagen peptides can be applied to various fields such as medicines and foods, since the odor, color, and redness are removed and the low molecular weight ratio is high.
바람직하기로, 본 발명의 콜라겐 펩티드는 비만 개선, 예방 및 치료 활성이 있어, 약학적 조성물 또는 식품 조성물로 바람직하게 적용이 가능하다. Preferably, the collagen peptide of the present invention has an activity of improving, preventing and treating obesity, and thus can be preferably applied to a pharmaceutical composition or a food composition.
약학적 조성물로 적용되는 경우, 콜라겐 펩티드 이외에 제형, 사용방법 및 사용목적에 따라 약리학적으로 허용 가능한 담체 또는 부형제를 더욱 포함할 수 있다. When applied as a pharmaceutical composition, it may further include a pharmacologically acceptable carrier or excipient in addition to the collagen peptide, depending on the formulation, the method of use, and the intended use.
약학적으로 허용가능한 담체 또는 부형제로는 물, 덱스트린, 칼슘카보네이트, 락토스, 프로필렌 글리콜, 리퀴드 파라핀, 생리식염수, 덱스트로스, 수크로즈, 솔비톨, 만니톨, 자이리톨, 에리스리톨, 말티톨, 전분, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 폴리비닐피롤리돈, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유가 있으며, 이들은 1종 이상 사용될 수 있으나, 이에 한정되는 것은 아니며 통상의 담체 및 부형제는 모두 사용가능하다. 또한, 항비만 조성물을 약제화하는 경우, 통상의 충진제, 증량제, 결합제, 붕해제, 계면활성제, 항응집제, 윤활제, 습윤제, 향료, 유화제 또는 방부제 등을 더욱 포함할 수 있다.Pharmaceutically acceptable carriers or excipients include water, dextrin, calcium carbonate, lactose, propylene glycol, liquid paraffin, physiological saline, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gelatin, calcium phosphate , Calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. These may be used alone or in combination, but are not limited thereto Conventional carriers and excipients are all usable. In addition, when the anti-obesity composition is weakly formulated, it may further contain conventional fillers, extenders, binders, disintegrators, surfactants, anti-coagulants, lubricants, wetting agents, flavorings, emulsifiers or preservatives.
본 발명의 조성물은 경구 투여하거나 비경구 투여할 수 있으며, 투여량은 투여방법, 복용자의 연령, 성별 및 체중, 건강 상태, 배설률, 식이, 투여시간 및 질환의 중증도 등을 고려하여 결정하는 것이 좋다. 일례로, 본 발명의 콜라겐 펩티드는 1일 0.1 내지 100 ㎎/㎏(체중)으로 1회 이상 투여가능하다. 그러나 상기한 투여량은 예시하기 위한 일례에 불과하며 상기 범위에 한정되진 않는다.
The composition of the present invention can be administered orally or parenterally. The dose is determined in consideration of the administration method, the age, sex and weight of the recipient, health condition, excretion rate, diet, administration time and severity of disease . For example, the collagen peptide of the present invention can be administered at least once at a dose of 0.1 to 100 mg / kg (body weight) per day. However, the above-mentioned dosage is merely an example for illustrative purposes and is not limited to the above range.
또한, 본 발명에 따른 어류 유래 콜라겐 펩티드는 비만 예방 및 개선을 목적으로 하는 식품 조성물로 적용되는 경우, 콜라겐 펩티드를 그대로 첨가하거나, 다른 식품 또는 식품 성분과 함께 사용될 수 있다. In addition, when the fish-derived collagen peptide according to the present invention is applied to a food composition for the purpose of preventing and improving obesity, the collagen peptide may be added as it is or may be used together with other foods or food ingredients.
상기 식품 조성물은 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food) 및 식품 첨가제(food additives) 등의 모든 형태를 포함한다. 상기 유형의 식품 조성물은 당 업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.The food composition includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.
이때 식품의 종류는 특별히 제한되지 않으며, 일례로 육류, 음료수, 초콜릿, 스낵류, 과자류, 피자, 라면, 기타 면류, 검류, 아이스크림류, 알코올 음료, 비타민 복합제, 주류 및 그 밖의 건강보조식품류일 수 있으나, 이에 한정되는 것은 아니다. In this case, the kind of the food is not particularly limited and may be, for example, meat, beverage, chocolate, snack, confectionery, pizza, ramen, other noodles, gourd, ice cream, alcoholic beverage, vitamin complex, , But is not limited thereto.
이러한 어류 유래 콜라겐 펩티드의 양은 전체 식품 중량의 0.01 내지 50 중량%, 바람직하게는 0.1 내지 20 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다.
Such an amount of fish-derived collagen peptide may be added in an amount of 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food, and the health beverage composition may be added in an amount of 0.02 to 10 g, preferably 0.3 to 1 g It can be added in a ratio.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예, 제조예를 제시한다. 그러나 하기의 예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 에 의해 본 발명의 내용이 한정되는 것은 아니다.
Hereinafter, preferred examples, experimental examples, and production examples are provided to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited thereto.
실시예 1: 효소의 순차 처리 및 녹차잎을 사용한 콜라겐 펩티드의 제조Example 1: Sequential treatment of enzymes and preparation of collagen peptides using green tea leaves
틸라피아(Tilapia) 물고기 비늘 1.0kg을 상수 10L로 세척한 후 상수 3L에 넣고 교반시켰다. 이 용액에 건조된 녹차잎 100g을 첨가한 후, 프로테아제로서 알칼라제를 10g을 가하고, 용액의 pH를 8로 조정하여 60℃에서 6시간 효소 반응을 행하였다. 여기에 다시 프로테아제로서 수미자임을 10g 첨가하고, 용액의 pH를 5로 조정하여 40℃에서 6시간 효소 반응을 행하였다. 1.0 kg of Tilapia fish scales were washed with 10 L of constant water and then put into 3 L of constant water and stirred. After adding 100 g of dried green tea leaves to this solution, 10 g of alcalase was added as a protease, the pH of the solution was adjusted to 8, and the enzyme reaction was carried out at 60 ° C for 6 hours. To this was further added 10 g of suizyme as a protease, the pH of the solution was adjusted to 5, and the enzyme reaction was carried out at 40 캜 for 6 hours.
반응 종료 후, 용액을 90℃ 이상으로 가열하여 효소를 실활시키고, 여과보조제 20g을 첨가하여 정밀 여과를 행한 후, 미리 충진한 흡착수지(HP20)를 SV1의 속도로 통과하고, 통과액은 미리 충진한 약산성 양이온교환수지(Diaion WK60L)과 약염기성 음이온교환수지(Trilite AW90)를 충진한 칼럼을 각각 SV3의 속도로 통과하였다. 이어 통과액을 농축한 후 분무 건조시켜 분말상 콜라겐 펩티드 조성물을 얻었다. 사용한 녹차잎의 폴리페놀 함량은 112 mg/g이었으며, 최종 제조된 콜라겐 펩티드에서는 폴리페놀이 검출되지 않았다.
After the completion of the reaction, the solution was heated to 90 DEG C or higher to inactivate the enzyme, and 20 g of the filter aid was added to perform microfiltration. Thereafter, the previously adsorbed adsorption resin HP20 was passed at the rate of SV1, A column filled with a weakly acidic cation exchange resin (Diaion WK60L) and a weakly basic anion exchange resin (Trilite AW90) was passed through at SV3 velocity. Then, the passing solution was concentrated and spray-dried to obtain a powdery collagen peptide composition. The polyphenol content of the green tea leaves used was 112 mg / g, and polyphenol was not detected in the final collagen peptide.
비교예 1: 단일 효소처리에 의한 콜라겐 펩티드의 제조Comparative Example 1: Preparation of collagen peptide by single enzyme treatment
별도로 시판하는 틸라피아(Tilapia) 비늘 유래의 시료를 콜라겐 펩티드 조성물(A)로 하였다. A sample derived from a commercially available tilapia scales was used as a collagen peptide composition (A).
통상의 방법에 의한 일반 콜라겐 펩티드의 제조는 틸라피아(Tilapia) 물고기 비늘 1.0kg을 상수 10L로 세척한 후 상수 3L에 넣고 교반시켰다. 이 용액에 프로테아제로서 알칼라제를 20g 가하고, 용액의 pH를 8로 조정하여 60℃에서 12 시간 효소 반응을 행하였다. The preparation of general collagen peptide by the conventional method was carried out by washing 1.0 kg of Tilapia fish scales with 10 L of constant water, adding 3 L of constant water and stirring. To this solution was added 20 g of alcholase as a protease, and the pH of the solution was adjusted to 8, and the enzyme reaction was carried out at 60 DEG C for 12 hours.
반응 종료 후, 용액을 90℃ 이상으로 가열하여 효소를 실활시키고, 여과보조제 20g을 첨가하여 정밀 여과를 행한 후, 활성탄을 비늘 중량대비 5% 사용하여 불순물과 색, 냄새를 제거하였으며 이를 2회 반복하였다. 여액은 농축한 후 분무 건조시켜 분말상 콜라겐 펩티드 조성물을 얻었다.
After completion of the reaction, the solution was heated to 90 ° C or higher to inactivate the enzyme, and 20 g of the filter aid was added thereto to perform microfiltration. Then, 5% of the activated carbon was used to remove impurities, color and odor. Respectively. The filtrate was concentrated and then spray-dried to obtain a powdery collagen peptide composition.
비교예 2: 효소 동시 처리를 수행한 콜라겐 펩티드의 제조Comparative Example 2: Preparation of collagen peptide subjected to simultaneous treatment with enzyme
틸라피아(Tilapia) 물고기 비늘 1.0kg을 상수 10L로 세척한 후 상수 3L에 넣고 교반시켰다. 이 용액에 프로테아제로서 알칼라제를 10g을 가하고, 용액의 pH를 8로 조정하여 60℃에서 6시간 효소 반응을 행하였다. 여기에 다시 프로테아제로서 수미자임을 10g을 첨가하고, 용액의 pH를 5로 조정하여 40℃에서 6시간 효소 반응을 행하였다. 1.0 kg of Tilapia fish scales were washed with 10 L of constant water and then put into 3 L of constant water and stirred. To this solution was added 10 g of alcholase as a protease, the pH of the solution was adjusted to 8, and the enzyme reaction was carried out at 60 DEG C for 6 hours. To this was further added 10 g of suizyme as a protease, and the pH of the solution was adjusted to 5, and the enzyme reaction was carried out at 40 ° C for 6 hours.
반응 종료 후, 용액을 90℃ 이상으로 가열하여 효소를 실활시키고, 여과보조제 20g을 첨가하여 정밀 여과를 행한 후, 미리 충진한 흡착수지를 SV1의 속도로 통과하고 통과액은 미리 충진한 약산성 양이온 및 약염기성 음이온교환수지를 각각 SV3(2.5L/min)의 속도로 통과하고 농축한 후 분무 건조시켜 분말상 콜라겐 펩티드 조성물을 얻었다.
After completion of the reaction, the solution was heated to 90 DEG C or higher to inactivate the enzyme, and 20 g of the filtration aid was added to perform microfiltration. The adsorbent resin previously charged was passed through at a rate of SV1, The weakly basic anion exchange resin was passed through SV3 (2.5 L / min) and concentrated, followed by spray drying to obtain a powdery collagen peptide composition.
실험예 1: 분자량 분석Experimental Example 1: Molecular weight analysis
상기 실시예 1, 비교예 1 및 2에서 얻어진 콜라겐 펩티드의 분자량을 분석하였다.The molecular weights of the collagen peptides obtained in Example 1 and Comparative Examples 1 and 2 were analyzed.
도 1은 (a) 실시예 1, (b) 비교예 1 및 (c) 비교예 2의 콜라겐 펩티드의 분자량 분포를 보여주는 그래프이다. 도 1에 나타난 바와 같이 비교예 1의 알칼라제 단독 처리의 경우 분자량이 가장 높았으며, 비교예 2의 알칼라제와 수미자임을 동시에 처리한 경우가 낮았고, 본 발명에 따른 실시예 1의 알칼라제 처리 후 수미자임 처리 시 순차적으로 분자량이 적어짐을 알 수 있었다.
FIG. 1 is a graph showing the molecular weight distribution of the collagen peptide of (a) Example 1, (b) Comparative Example 1 and (c) Comparative Example 2. FIG. As shown in Fig. 1, the molecular weight of the alcalase-only treatment of Comparative Example 1 was the highest, while the treatment of both the alcalase and the suzimizer of Comparative Example 2 was low, It was found that the molecular weight was gradually decreased in the treatment with water after the colorimetric treatment.
이때 실시예 1, 비교예 1 및 2의 콜라겐 펩티드의 평균 분자량을 하기 조건에서 겔 여과 크로마토그래피(GPC)를 행하여 측정하였으며, 분자량 마커의 유지 시간에 기초하여 별도로 제조한 검량선을 이용하여, 평균 분자량을 산출하였으며, 얻어진 결과를 도 2에 나타내었다.The average molecular weights of the collagen peptides of Example 1 and Comparative Examples 1 and 2 were measured by gel filtration chromatography (GPC) under the following conditions. Using a calibration curve separately prepared on the basis of the retention time of the molecular weight markers, And the obtained results are shown in Fig.
(분석 조건)(Analysis condition)
칼럼: Waters Ultrahydrogel120(300ㅧ7.8 mm) Column: Waters Ultrahydrogel 120 (300 ㅧ 7.8 mm)
이동상: 45 ％ 아세토니트릴(0.1 ％ 트리플루오로아세트산 함유) Mobile phase: 45% acetonitrile (containing 0.1% trifluoroacetic acid)
유속: 0.8 ml/분 Flow rate: 0.8 ml / min
검출 파장: 220 nm Detection wavelength: 220 nm
도 2는 (a) 실시예 1, (b) 비교예 1 및 (c) 비교예 2의 콜라겐 펩티드의 평균 분자량 분포를 보여주는 그래프이다.2 is a graph showing the average molecular weight distribution of collagen peptides of (a) Example 1, (b) Comparative Example 1 and (c) Comparative Example 2.
실시예 1의 콜라겐 펩티드는 평균 분자량이 90∼2800의 펩티드 집합물로서, 평균분자량 1500 이하의 펩티드가 전체의 65% 이상을 차지하였다. 구체적으로, 평균분자량 850 이하의 펩티드가 28.72％, 평균분자량 850∼1500의 펩티드가 36.61％, 평균분자량 1500∼2000의 펩티드가 27.42％, 평균분자량 2000 이상의 펩티드가 7.26％였다.The collagen peptide of Example 1 was a peptide aggregate having an average molecular weight of 90 to 2800, and the peptide having an average molecular weight of 1500 or less occupied 65% or more of the whole. Specifically, 28.72% of peptides having an average molecular weight of 850 or less, 36.61% of peptides having an average molecular weight of 850 to 1500, 27.42% of peptides having an average molecular weight of 1500-2000, and 7.26% of peptides having an average molecular weight of 2000 or more.
이와 비교하여, 비교예 1의 콜라겐 펩티드는 평균 분자량이 160∼3600으로, 상세한 비율은 평균분자량 850 이하의 펩티드가 12.95％, 평균분자량 850∼1500의 펩티드가 25.03％, 평균분자량 1500∼2100의 펩티드가 24.45％, 평균분자량 2100 이상의 펩티드가 27.5％였다. In comparison, the collagen peptide of Comparative Example 1 had an average molecular weight of 160 to 3600, a detailed ratio of 12.95% of a peptide having an average molecular weight of 850 or less, 25.03% of a peptide having an average molecular weight of 850 to 1500 and a peptide having an average molecular weight of 1500 to 2100 Of 24.45% and 27.5% of peptides having an average molecular weight of 2100 or more.
또한, 비교예 2의 콜라겐 펩티드는 평균 분자량이 90∼3600으로, 상세한 비율을 보면 평균분자량 850 이하의 펩티드가 14.57％, 평균분자량 850∼1500의 펩티드가 23.46％, 평균분자량 1500∼2300의 펩티드가 44.62 ％, 평균분자량 2300 이상의 펩티드가 17.35％였다.
The collagen peptide of Comparative Example 2 had an average molecular weight of 90 to 3600, a detailed ratio of peptides having an average molecular weight of 850 or less was 14.57%, peptides having an average molecular weight of 850 to 1500 were 23.46%, peptides having an average molecular weight of 1500 to 2300 44.62%, and the peptide having an average molecular weight of 2300 or more was 17.35%.
실험예 2: 성상 분석Experimental Example 2: Analysis of Properties
상기 실시예 및 비교예에서 얻어진 콜라겐 펩티드의 성상 및 관능을 하기 표 1에 나타내었다. 하기 표 1의 결과를 보면, 실시예 1의 콜라겐 펩티드는 원료 및 비교예 1, 2에서 얻어진 콜라겐 펩티드와 품질면에서 큰 차이를 나타냄을 알 수 있다.The properties and the functionalities of the collagen peptides obtained in the above Examples and Comparative Examples are shown in Table 1 below. From the results shown in Table 1, it can be seen that the collagen peptide of Example 1 is significantly different from the collagen peptide obtained in the raw materials and Comparative Examples 1 and 2 in terms of quality.
*: 시판되는 틸라피아 비늘 유래 시료(Strength: None -, about + <-----> Strong +++++)
*: Samples derived from commercial tilapia scales
실험예 3: 비만억제 효과 분석Experimental Example 3: Analysis of obesity inhibitory effect
본 발명에 의한 콜라겐 펩티드를 사용하여 체중관련 기능성에 대한 분석과 효능을 평가하였다. 이하 콜라겐 펩티드의 경구투여에 의한 비만억제기능에 대하여 설명한다.The collagen peptides according to the present invention were used to analyze the weight-related functionality and evaluate its efficacy. Hereinafter, the function of suppressing obesity by oral administration of collagen peptide will be described.
(고지방 식이 섭취 생쥐에 대한 콜라겐 펩티드 영향)(Effect of Collagen Peptides on High Fat Diet-fed Mice)
실험동물Experimental animal
ICR 암컷 생쥐 (3주령)는 ORIENT BIO Inc (Korea)로부터 구입하였고, 24℃ 에서 12시간 밤/낮 주기로 유지하였다. 구입 후 1주일 동안 환경에 적응을 시킨 후 50마리의 생쥐를 무작위로 5개 그룹으로 10마리씩 나누었다 (n=10). 생쥐에게 고지방 식이 (a high-fat diet, HFD)는 Research Diets사의 Rodent Diet with 60% kcal Fat을 사용하였다. 생쥐는 물과 먹이를 자유롭게 섭취하게 하였고 먹이는 매일 신선하게 제공해 주며 섭취량을 측정하였으며, 체중은 일주일에 두 번씩 측정하였다. 고지방 식이를 섭취한 생쥐에게 14주 동안 일주일에 두 번씩 식도 내 삽관 방식으로 주입하였다. 각 콜라겐 펩티드는 체중에 비례하여 100 mg/kg씩 주입하였다. 콜라겐 펩티드를 고지방 식이와 함께 섭취한 생쥐의 체중변화를 관찰하고, 그 결과를 표 1에 나타내었다.
ICR female mice (3 weeks old) were purchased from ORIENT BIO Inc (Korea) and maintained at 24 ° C for 12 hours at night / day. 50 mice were randomly divided into 5 groups (n = 10) after adaptation to the environment for one week after purchase. For mice, a high-fat diet (HFD) was a Rodent Diet with 60% kcal Fat from Research Diets. Mice were allowed free access to water and food, daily feeding was provided freshly, intake was measured, and body weight was measured twice a week. Intra esophageal intubation was given to mice fed a high fat diet twice a week for 14 weeks. Each collagen peptide was injected at 100 mg / kg in proportion to body weight. The weight change of the mice fed with the collagen peptide together with the high fat diet was observed, and the results are shown in Table 1.
샘플 추출과 분석방법Sample extraction and analysis method
실험 하루 전부터 먹이를 주지 않은 상태에서 경추탈골로 생쥐를 죽인 후 EDTA 처리된 채혈용 튜브에 혈액을 모았다. 얻어진 혈액은 4℃에서 5분간 원심분리하여 혈장을 분리한 후 사용 전까지 -80℃에서 보관하였다. 생쥐를 해부하여 간과 지방 조직을 적출하여 각각의 무게를 측정하였다. 적출한 간을 1g씩 3부분으로 나눠서 액체 질소에 넣어서 얼린 후 전체 RNA와 지방을 추출하였다.The mice were killed with cervical dislocations in the absence of food for one day prior to the experiment and blood was collected in EDTA-treated blood collection tubes. The obtained blood was centrifuged at 4 ° C for 5 minutes to separate the plasma and stored at -80 ° C until use. The mice were dissected and liver and adipose tissue were removed and weighed. The extracted liver was divided into three portions of 1 g each, which was then frozen in liquid nitrogen and extracted with total RNA and fat.
혈장의 전체 콜레스테롤과 트리글리세리드 양은 Enzychrome HDL 과 LDL/VLDL 분석 키트(BioAssay System)와 트리글리세리드 (GPO-Trinder) 키트(Sigma-Aldrich)를 사용하였다. 간 지방은 클로로포름/메탄올 혼합액을 이용하여 분리한 후 (Folch 등 1957), 2-프로판올에 녹여서 간의 전체 콜레스테롤과 트리글리세리드를 Enzychrome HDL 과 LDL/VLDL 분석 키트를 사용하여 측정하였다. 이때 각 그룹 분류는 하기와 같다.Enzychrome HDL and LDL / VLDL assay kit (BioAssay System) and triglyceride (GPO-Trinder) kit (Sigma-Aldrich) were used for plasma total cholesterol and triglyceride content. Liver fat was separated using chloroform / methanol mixture (Folch et al. 1957), dissolved in 2-propanol, and total cholesterol and triglycerides of liver were measured using Enzychrome HDL and LDL / VLDL assay kit. Each group classification is as follows.
- 대조군(Control):고지방 식이 섭취 그룹- Control (control): high fat dietary intake group
- 그룹 A: 고지방 식이 섭취 및 시료(시판하는 틸라피아 비늘 유래 시료) 주입 그룹
- Group A: Intake of high fat diets and samples (samples from commercial tilapia scales) injection group
- 그룹 B: 고지방 식이 섭취 및 비교예 1의 콜라겐 펩티드 주입 그룹- Group B: high fat dietary intake and collagen peptide injection group of Comparative Example 1
- 그룹 C: 고지방 식이 섭취 및 비교예 2의 콜라겐 펩티드 주입 그룹Group C: High fat diet intake and collagen peptide injection group of Comparative Example 2
- 그룹 D: 고지방 식이 섭취 및 실시예 1의 콜라겐 펩티드 주입 그룹
Group D: high fat diet intake and collagen peptide injection group of Example 1
(1) 생쥐의 체중비 및 사료요구율 측정(1) Measuring the body weight ratio and feed conversion ratio of mice
하기 표 2는 콜라겐 펩티드를 투여한 고지방식이 생쥐의 대조군에 대한 체중비, 및 사료요구율을 측정한 결과를 나타낸다. Table 2 below shows the results of measuring the body weight ratio of the mice to the control group of the high-fat diet system fed with the collagen peptide and the feed conversion ratio.
(body wt, % control)Weight ratio
(body wt,% control)
(food gain ratio, %)Feed rate
(food gain ratio,%)
상기 표 2를 참조하면, 대조군 대비 그룹 B의 경우는 체중이 증가하였고, 그룹 A, C 및 D는 감소하는 경향을 나타내었으며, 특히 본 발명에 따른 실시예 1의 콜라겐 펩티드를 투여한 그룹 D의 경우 체중이 크게 감소하였으며, 사료 요구율 또한 줄어드는 경향을 나타내었다.
As shown in the above Table 2, in the case of Group B, the body weight was increased and the groups A, C and D were decreased in comparison with the control group. In particular, in Group D of Example 1 of the present invention in which the collagen peptide was administered Weight loss was significantly reduced and feed conversion ratio was also decreased.
(2) 생쥐의 복부 지방층 및 간의 중량 측정(2) Abdominal fat layer and liver weight measurement of mice
체중 측정 후 생쥐의 간과 복부 지방층을 적출하여 무게를 측정하고, 그 결과를 표 3에 나타내었다. 하기 표 3은 콜라겐 펩티드를 투여한 고지방식이 생쥐의 복부 지방층 및 간의 무게를 측정한 결과를 나타낸다.After the body weight measurement, the liver and abdominal fat layer of the mice were extracted and weighed, and the results are shown in Table 3. Table 3 shows the result of measuring the weight of the abdominal fat layer and the liver of the mice in a high fat diet system in which the collagen peptide was administered.
상기 표 3에 나타낸 바와 같이, 모든 그룹의 간의 무게는 거의 차이가 없었으나, 콜라겐 펩티드를 주입한 생쥐의 경우 복부 지방층의 무게는 대조군보다 감소하였다. 특히, 본 발명에 따른 실시예 1의 콜라겐 펩티드를 투여한 그룹 D의 경우에서 가장 큰 감소 경향을 나타내었다.
As shown in Table 3, the weight of the liver of all groups was not different, but the weight of the abdominal fat layer of the mice injected with the collagen peptide was lower than that of the control group. In particular, the group D in which the collagen peptide of Example 1 according to the present invention was administered showed the greatest decreasing tendency.
(3) 혈장 (3) Plasma 트리글리세리드Triglyceride , 혈장 글리세롤, 간의 , Plasma glycerol, liver 트리글리세리드의Triglyceride 농도를 측정 Measure concentration
체중 측정 후 혈액을 얻어 혈장 트리글리세리드 농도와 혈장 글리세롤 농도 그리고 간의 트리글리세리드의 농도를 측정하고, 그 결과를 표 4 및 표 5에 나타내었다. 하기 표 4는 콜라겐 펩티드를 투여한 고지방식이 생쥐의 혈장 트리글리세리드, 혈장 글리세롤 및 간 트리글리세리드를 측정한 결과를 나타낸다.After measuring the body weight, blood was taken and plasma triglyceride concentration, plasma glycerol concentration, and liver triglyceride concentration were measured, and the results are shown in Tables 4 and 5. Table 4 below shows the results of measurement of plasma triglycerides, plasma glycerol and liver triglycerides in mice in a high fat diet system supplemented with collagen peptide.
(mg/dl)Plasma glycerol
(mg / dl)
(mg/dl)Liver glycerol
(mg / dl)
상기 표 4를 참조하면, 대조군에 비해 콜라겐 펩티드를 처리한 그룹에서 전혈 트리글리세리드와 혈장 글리세롤 및 간의 트리글리세리드 농도가 감소하였다. 각각 대조군, A, B, C, D 그룹의 혈장 트리글리세리드 농도는 27.53±6.15, 26.01±3.35, 22.37±2.68, 19.85±3.74, 15.52±4.26 mg/dl로 D 그룹이 가장 낮았다. Referring to Table 4 above, the concentration of whole blood triglyceride, plasma glycerol, and triglyceride in the collagen peptide-treated group was lower than that of the control group. The concentrations of plasma triglycerides in the control, A, B, C and D groups were 27.53 ± 6.15, 26.01 ± 3.35, 22.37 ± 2.68, 19.85 ± 3.74 and 15.52 ± 4.26 mg / dl, respectively.
하기 표 5는 콜라겐 펩티드를 투여한 고지방식이 생쥐의 혈장 총 콜레스테롤, 혈장 총 LDL, 간 총 콜레스테롤 및 간 총 LDL를 측정한 결과를 나타낸다.Table 5 below shows the results of measurement of plasma total cholesterol, plasma total LDL, liver total cholesterol, and liver total LDL in a high fat diet system in which the collagen peptide was administered.
(mg/dl)Plasma total cholesterol
(mg / dl)
(mg/dl)Liver cholesterol
(mg / dl)
(mg/dl)Liver LDL
(mg / dl)
(mg/dl)Plasma LDL
(mg / dl)
상기 표 5를 참조하면, 각각 대조군, A, B, C, D 그룹의 혈장의 콜레스테롤농도는 265.75±6.67, 253.65±11.34, 259.87±17.36, 223.21±10.45, 190.55±11.23 mg/dl로 C, D 그룹의 생쥐에서 콜레스테롤 농도가 감소함을 알 수 있다. Referring to Table 5, the plasma cholesterol concentrations of the control groups A, B, C and D were 265.75 ± 6.67, 253.65 ± 11.34, 259.87 ± 17.36, 223.21 ± 10.45 and 190.55 ± 11.23 mg / And the cholesterol concentration in the group of mice decreased.
그리고 간의 콜레스테롤 농도는 각각 대조군, A, B, C, D 그룹의 순서로 190.72±8.43, 169.65±9.12, 170.12±8.21, 165.55±7.25, 147.37±10.43 mg/dl로 각 콜라겐 펩티드를 처리한 모든 그룹에서 대조군보다 감소하였다. The concentrations of cholesterol in the liver were 190.72 ± 8.43, 169.65 ± 9.12, 170.12 ± 8.21, 165.55 ± 7.25, and 147.37 ± 10.43 mg / dl in the order of the control group, A, B, Compared to the control group.
각 콜라겐 펩티드를 처리한 그룹의 간 및 혈장의 저밀도지단백 콜레스테롤(Low Density-Lipoprotein, LDL) 농도가 감소한 것을 관찰하였는데 C, D 그룹에서 간의 LDL 농도가 낮은 것을 확인하였다. (LDL) concentration in the liver and plasma of each group treated with collagen peptides was decreased. It was confirmed that the liver LDL concentration was low in the C and D groups.
상기한 실험 결과에 의하면 본 발명의 제조된 콜라겐 펩티드를 섭취할 경우 지방대사 및 비만억제에 효과가 우수한 것으로 나타났다.
According to the results of the above experiment, when the collagen peptide prepared according to the present invention was ingested, it was found to be excellent in fat metabolism and inhibition of obesity.
실험예 4: 단회 및 반복 투여 독성 시험Experimental Example 4: Single and repeated dose toxicity test
본 발명에 따른 콜라겐 펩티드를 경구 투여 시 독성 유발 여부를 확인하기 위해 단회 독성 및 4주 반복 투여 독성시험을 수행하였다.To confirm the toxicity of the collagen peptide according to the present invention upon oral administration, single-dose and four-week repeated dose toxicity tests were conducted.
단회 독성은 6주령 웅성 ICR 생쥐 각 6마리를 한 군으로 하여 실시예 1의 콜라겐 펩티드 수용액을 경구로 1,000∼5,000mg/kg체중으로 단회 투여 후 2주간 생존 여부를 살피고 실험동물을 안락사 후 부검을 통해 장기 이상 소견을 관찰하였다. 모든 농도의 투여군에서 사망한 동물은 없었고 장기 이상 소견도 발견되지 않아 독성이 없는 것으로 판단되었다.Single-dose toxicity was assessed by observing survival for 2 weeks after oral administration of collagen peptide solution of Example 1 at a dose of 1,000 to 5,000 mg / kg body weight per 6-week-old male ICR mice, The long - term abnormal findings were observed. There were no deaths in all dose groups and no abnormal findings were found.
또한, 하루 한 번 28일간 반복 투여하면서 체중변화, 일반 증상 및 생존 여부를 살피고 실험동물을 안락사 후 부검을 통해 장기이상 소견을 관찰하였다. 모든 농도의 투여군에서 사망한 동물은 없었고 장기 이상 소견도 발견되지 않았다.
In addition, we repeatedly administered once a day for 28 days to examine changes in body weight, general symptoms, and survival. There were no deaths in any dose groups and no abnormal findings were found.
이하, 본 발명의 실시예 1에서 제조된 콜라겐 펩티드를 함유한 조성물의 구성을 보다 구체적으로 설명한다. 그러나 본 발명의 조성물이 이들 제제예 및 제형예에 한정되는 것은 아니다.
Hereinafter, the composition of the composition containing the collagen peptide prepared in Example 1 of the present invention will be described in more detail. However, the composition of the present invention is not limited to these formulation examples and formulation examples.
제제예 1: 산제의 제조Formulation Example 1: Preparation of powder
통상의 산제의 제조방법에 따라 실시예 1의 콜라겐 펩티드 300mg, 유당 100mg, 및 탈크 10mg을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
300 mg of collagen peptide of Example 1, 100 mg of lactose, and 10 mg of talc were mixed according to a conventional powder preparation method and filled in an airtight container to prepare a powder.
제제예 2: 정제의 제조Formulation Example 2: Preparation of tablets
통상의 정제의 제조방법에 따라 실시예 1의 콜라겐 펩티드인 50mg, 옥수수전분 100mg, 유당 100mg, 및 스테아린산 마그네슘 2mg을 혼합하고 타정하여 정제를 제조하였다.
The tablets were prepared by mixing 50 mg of the collagen peptide of Example 1, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate in accordance with a conventional method for producing tablets.
제제예 3: 캡슐제의 제조Formulation Example 3: Preparation of capsules
통상의 캡슐제 제조방법에 따라 실시예 1의 콜라겐 펩티드인 50mg, 옥수수전분 100mg, 유당 100mg, 및 스테아린산 마그네슘 2mg을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
The collagen peptide of Example 1 (50 mg), corn starch (100 mg), lactose (100 mg) and magnesium stearate (2 mg) were mixed and filled in gelatin capsules according to a conventional capsule preparation method to prepare capsules.
제제예 4: 주사제의 제조Formulation Example 4: Preparation of injection
통상의 주사제의 제조방법에 따라 실시예 1의 콜라겐 펩티드인 50 g, 주사용 멸균 증류수 적량, 및 pH 조절제 적량을 혼합하여 1 앰플당 (2㎖) 상기의 성분 함량으로 제조하였다.
50 g of the collagen peptide of Example 1, sterile distilled water for injectable use, and an appropriate amount of pH adjuster were mixed according to the usual injection preparation method to prepare the above components in an amount (2 ml) per ampoule.
제제예 5: 액제의 제조Formulation Example 5: Preparation of a liquid preparation
통상의 액제의 제조방법에 따라 실시예 1의 콜라겐 펩티드 100mg, 이성화당 10g, 만니톨 5g을 정제수에 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조하였다.
100 mg of the collagen peptide of Example 1, 10 g of isomerized sugar, and 5 g of mannitol were dissolved in purified water and the lemon flavor was added in an appropriate amount. Then, the above components were mixed and then purified water was added to the whole, Ml, and then filled in a brown bottle and sterilized to prepare a liquid preparation.
제형예 1: 건강음료Formulation Example 1: Health drinks
멸균하여 준비한 1000 ml 정제수에 실시예 1의 콜라겐 펩티드 0.1g을 첨가한 다음, 여기에 구연산 1g과 유자과육농축액 1g, 올리고당 100g을 첨가하여 60분간 85℃에서 교반하면서 가열하였다. 이렇게 만들어진 용액을 여과하여 멸균된 2L 용기에 취득하여 밀봉 멸균한 뒤 보관하였다. 제조된 건강음료의 pH는 3.5, 당도는 9%였다.
After adding 0.1 g of the collagen peptide of Example 1 to 1000 ml of purified water prepared by sterilization, 1 g of citric acid, 1 g of citron juice concentrate, and 100 g of oligosaccharide were added and heated for 60 minutes at 85 캜 with stirring. The thus-prepared solution was filtered and sterilized in a sterilized 2 L container, and stored. The pH of the prepared health drink was 3.5 and the sugar content was 9%.
제형요 2: 청량음료Formulation 2: Soft drinks
상기 실시예 1에서 제조된 콜라겐 펩티드는 0.1g을 사이다와 같은 소프트 음료 시럽 1000ml에 용해하는 것을 제외하고는 제조예 1과 동일하게 제조하였다.
The collagen peptide prepared in Example 1 was prepared in the same manner as in Preparation Example 1, except that 0.1 g of the collagen peptide was dissolved in 1000 ml of soft drink syrup such as cider.
제형요 3: 스포츠 음료Formulation yo 3: sports drinks
상기 실시예 1에서 제조된 콜라겐 펩티드는 0.1g을 스포츠 드링크(상품명: 포카리스웨트) 1000ml에 첨가한 것을 제외하고는 제조예 1과 동일하게 제조하였다.The collagen peptide prepared in Example 1 was prepared in the same manner as in Preparation Example 1, except that 0.1 g of the collagen peptide was added to 1000 ml of sports drink (trade name: Pocari Sweat).
Claims (13)
상기 콜라겐 펩티드 여과물을 흡착수지 및 이온교환수지에 통과시켜 정제하는 단계; 및
농축, 건조하여 콜라겐 펩티드를 회수하는 단계를 포함하는 어류 유래 콜라겐 펩티드의 제조방법.Adding a green tea leaf, an extract thereof or an extractive by-product of the green tea leaf together with a protein hydrolyzing enzyme to a raw material containing fish scales or a shell, performing an enzymatic decomposition process, and then filtering to obtain a collagen peptide filtrate;
Passing the collagen peptide filtrate through an adsorption resin and an ion exchange resin to purify the collagen peptide filtrate; And
Concentrating, and drying the collagen peptide to recover the collagen peptide.
The fish-derived collagen peptide according to claim 11, wherein the fish-derived collagen peptide has 28.72% of peptides having an average molecular weight of 850 or less, 36.61% of peptides having an average molecular weight of 850 to 1500, 27.42% of peptides having an average molecular weight of 1500-2000, 7.26%. ≪ / RTI >
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120064957A KR101415225B1 (en) | 2012-06-18 | 2012-06-18 | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120064957A KR101415225B1 (en) | 2012-06-18 | 2012-06-18 | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130141877A KR20130141877A (en) | 2013-12-27 |
| KR101415225B1 true KR101415225B1 (en) | 2014-07-04 |
Family
ID=49985670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120064957A KR101415225B1 (en) | 2012-06-18 | 2012-06-18 | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101415225B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102204369B1 (en) * | 2020-05-19 | 2021-01-19 | 주식회사 뷰티콜라겐 | Method for manufacturing collagen with improved odor and viscosity and food composition and cosmetic composition using the same |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016076647A1 (en) * | 2014-11-13 | 2016-05-19 | 아미코젠주식회사 | Method for preparing collagenase and method for preparing collagen tripeptide using same |
| CN104543920B (en) * | 2014-12-05 | 2016-12-07 | 浙江省海洋水产研究所 | A kind of preparation method of dried fish powder flavourings |
| CN106632605B (en) * | 2016-12-22 | 2020-06-16 | 浙江海洋大学 | Active peptide prepared from tuna leftovers and having liver injury repair effect |
| KR102144405B1 (en) * | 2018-06-14 | 2020-08-12 | 김구환 | Composition for promoting formation of new blood vessels and method for producing the same |
| CN109735591B (en) * | 2019-03-14 | 2020-11-10 | 舜甫科技(固安)有限公司 | Bovine bone collagen peptide and production method thereof |
| KR102406037B1 (en) * | 2019-06-27 | 2022-06-10 | 강릉원주대학교산학협력단 | Composition for antiaging comprising hydrolysates from Scomberomorus niphonius |
| KR102322269B1 (en) * | 2019-06-28 | 2021-11-05 | 주식회사 리앤씨바이오 | Calcium-collagen peptide chelate complex and method for preparing the same |
| CN112724245A (en) * | 2021-02-04 | 2021-04-30 | 海南华研胶原科技股份有限公司 | Method for extracting micromolecular collagen peptide by fish scale enzymolysis |
| CN117466993B (en) * | 2023-12-28 | 2024-03-08 | 山东鑫日海食品有限公司 | Membrane filtration purification method of deep sea fish collagen peptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254440A (en) * | 2006-03-27 | 2007-10-04 | Ihara Suisan Kk | Lipid metabolism-adjusting agent and lipid metabolism-adjusting food |
| KR20090106807A (en) * | 2008-04-07 | 2009-10-12 | 주식회사 키토라이프 | Preparation method of collagen peptides from fish scale |
| KR101071338B1 (en) * | 2008-07-07 | 2011-10-07 | 샘표식품 주식회사 | Method of Producing Collagen Peptide from Marine Organism and Collagen Peptide Produced by the Method |
-
2012
- 2012-06-18 KR KR1020120064957A patent/KR101415225B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007254440A (en) * | 2006-03-27 | 2007-10-04 | Ihara Suisan Kk | Lipid metabolism-adjusting agent and lipid metabolism-adjusting food |
| KR20090106807A (en) * | 2008-04-07 | 2009-10-12 | 주식회사 키토라이프 | Preparation method of collagen peptides from fish scale |
| KR101071338B1 (en) * | 2008-07-07 | 2011-10-07 | 샘표식품 주식회사 | Method of Producing Collagen Peptide from Marine Organism and Collagen Peptide Produced by the Method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102204369B1 (en) * | 2020-05-19 | 2021-01-19 | 주식회사 뷰티콜라겐 | Method for manufacturing collagen with improved odor and viscosity and food composition and cosmetic composition using the same |
| WO2021235591A1 (en) * | 2020-05-19 | 2021-11-25 | 주식회사 뷰티콜라겐 | Method for preparing collagen having reduced off-flavor and viscosity, and food and cosmetic composition using same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130141877A (en) | 2013-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101415225B1 (en) | Collagen peptide complex derived from fish, a preparation method thereof, and a use of the same | |
| JP4470212B2 (en) | Skin improver | |
| JP4738856B2 (en) | Method for producing N-acetylglucosamine-containing composition | |
| KR20120079964A (en) | Method for preparing fermented collagen peptide | |
| WO2010092941A1 (en) | Composition having vasodilation activity, process for producing same, and use of same | |
| CN104159912A (en) | Dipeptidyl peptidase-iv inhibitor | |
| WO2009035169A1 (en) | Peptide having anti-hypertensive activity | |
| JPWO2003075686A1 (en) | Method for producing SDG and its blended food and drink | |
| KR101449804B1 (en) | Antihypertensive composition comprising gelatin extract from skate skin and peptide isolated from the extract | |
| JPWO2016163245A1 (en) | Energy metabolism activator in muscle cells | |
| KR101566036B1 (en) | Composition for preventing or treating lung disease | |
| WO2021100614A1 (en) | Neuropsychological function improver comprising soybean peptide and/or collagen peptide | |
| KR20200048049A (en) | Antioxidant composition comprising extract of Apis mellifera male pupa | |
| JP5654290B2 (en) | Angiotensin converting enzyme inhibitory peptide and method for producing the same. | |
| KR20230110470A (en) | A composition for the prevention or treatment of hypertension containing edible insects hydrolysates and fractions thereof | |
| JP6369951B2 (en) | Dipeptidyl peptidase-IV inhibitor | |
| WO2005099486A1 (en) | Process for preparing lagerstroemia speciosa l. extract | |
| US20090263356A1 (en) | Anti-angiogenic composition comprising grain-derived component as active ingredient | |
| JP6083085B2 (en) | Angiotensin converting enzyme inhibitor and use thereof | |
| KR20110022472A (en) | Composition comprising the extract of sea algae for preventing and treating hypertension | |
| KR101629517B1 (en) | Oral composition | |
| KR20090055168A (en) | A composition containings hydrolysates, second hydrolysates or isolated active peptides of theragra chalcogramma as an active ingredient | |
| KR101489734B1 (en) | Composition comprising germinated black bean extracts for anti-hypertension | |
| JP6826726B2 (en) | Oral composition for promoting sugar uptake | |
| López-Huertas et al. | Antihypertensive peptides from olive oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180419 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20190418 Year of fee payment: 6 |